A Phase 1 interventional study of Placebo and PF-08656795 in Overweight and/or Obesity, sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity.
Doctors will check if each person meets the study conditions, including age, body weight, and general health. People with certain medical conditions will not be able to take part in the study.
The study is seeking participants who are:
People who want to join the study will first go through a screening period of up to 4 weeks. The study will look at how the study medicine is tolerated, including whether participants have any reactions. It will assess how they feel after receiving multiple doses. It will also measure the amounts of study medicine in the blood and urine over time.
Participants will take part in this study for about 24 to 40 weeks including treatment and follow-up period after the final dose. Treatment duration may vary depending on their assigned group.
3,767 studies on the registry are indexed under Overweight; 863 are open to participants now.
This study's planned enrollment of 150 is above the median of 73 across 3,263 interventional studies indexed under Overweight.
Browse Overweight studies →Pfizer is the lead sponsor of 3,323 studies on the registry; 145 are open to participants now.
Of its 597 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
- Individuals with clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurological, or allergic disease, are not eligible to participate.
Participants will receive PF-08656795 once a month or less frequently
Drug: PF-08656795
Participants will receive placebo once a month or less frequently
Drug: Placebo
Given subcutaneously (under the skin).
Given subcutaneously (under the skin).
Incidence of Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 12 weeks after last dose
Area Under the Curve from Time Zero to to time tau (AUCtau)
Time frame: 0 (pre-dose), 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 504, 672 hours post-dose
Maximum Observed Concentration (Cmax)
Time frame: 0 (pre-dose), 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 504, 672 hours post-dose
No study locations are listed for this record.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Start is estimated for Oct 2026; primary completion for Nov 2028, 24 months later.
Of 237 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 24 months is above that.
Counting every sponsor, half of 259 studies reached it within 9 months; a quarter within 5 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.